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Screening for Antinuclear Antibodies by 
Enzyme Immunoassay 
TROY D. JASKOWSKI, BS,I CARL SCHRODER, MS,I THOMAS B. MARTINS, BS,l 
C. LARS MOURITSEN, BS,1 CHRISTINE M. LITWIN, MD,J.2 AND HARRY R. HILL, MD1.2 
Indirect fluorescent antibody (IF A) is the most widely used method in 
clinical laboratories to screen for autoantibodies against a wide variety 
of nuclear antigens. Recently, a number of antinuclear antibody (ANA) 
enzyme immunoassay (ErA) screens have become commercially avail-
able and claim to be an alternative method to screen for ANAs. Given 
the subjectivity of technical interpretation of lFA and the high number 
of ANA negative samples, a suitable EIA method for ANA screening 
would be beneficial to clinical laboratories with large sample volumes. 
Five ANA EIA screens were compared (Elias, Helix, Sanofi, TheraTest 
and Zeus) to IFA using a buman epithelial cell line (HEp-2). Sera from 
601 patients submitted to our reference laboratory for autoimmune test-
ing, and from 202 normal bealthy blood donors, were included in this 
study. Samples with discordant results between IFA and EIA were fur-
ther analyzed using single antigen EIAs for SSA, SSB, Sm, RNP, Scl-
70, histones, dsDNA, and ssDNA. Analyses were based on clinically 
significant IFA titers of :2:1:160 as positive and <1:40 as negative. 
Detection of antinuclear antibody (ANA) is widely ac-
cepted as an important aid in the diagnosis of many 
rheumatic and connective tissue diseases such as sys-
temic lupus erythematosus (SLE), scleroderma, Sjo-
gren's syndrome (SS), and polymyositis.I.2 Antinuclear 
antibody testing by indirect fluorescent antibody (IFA) 
techniques using human epithelial cells (HEp-2) as an 
antigen substrate is the preferred method when screening 
for ANAs in patient sera. Screening for ANAs by IFA 
requires highly trained technical personnel is time con-
suming and subjective. Recently, a number of ANA EIA 
screens have become commercially available and claim 
to be an alternative method to screen for ANAs. If suit-
able, an EIA method could be very useful in the clinical 
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When compared to IFA, agreement, sensitivity and specificity for each 
ANA EIA screen were as follows: Elias: 87.0%, 69.5% and 97.9%; He-
lix: 94.6%, 90.2%, and 97.3%; Sanofi: 95.0%, 93.7%, and 95.9%; Ther-
aTest: 95.3%,97.7%, and 93.5%; Zeus: 87.1%, 96.2%, and 81.4%, re-
spectively. In conclusion, screening for ANAs by EIA using sCI'eral 
commercial assays was both sensitive and specific when compared to 
IFA. Moreover, the EIA is objective and much less labor intensive when 
screening a large number of dinical specimens. None of the EIAs were 
100% sensitive and, thus, may fail to detect a few of the nonspecific 
ANAs that demonstrate atypical as well as c1assicallFA patterns. The 
advantages of employing these nonsubjective assays to screen out the 
vast majority of ANA negative sera is clear. The authors still recom-
mend confirming titers and patterns of sera with positive EIA screens 
using classical IFA methods employing HEp-2 cells. (Key words: Anti-
nuclear antibodies; Indirect fluorescent antibody; Enzyme immunoas-
say; Autoantibodies) Am J C1in PathoI1996;105:468-473. 
laboratory for screening large numbers of specimens for 
ANAs. Our objective in this study was not to replace IFA 
with EIA, but rather to determine if current EIAs could 
be used to screen out ANA negative sera without signifi-
cant numbers of false negatives. Subsequently, IFA 
would be used to confirm a pattern and titer for sera with 
positive screens by EIA. 
MATERIALS AND METHODS 
Clinical Samples 
Sera from 601 patients submitted to our reference lab-
oratory for autoimmune testing and from 202 normal 
healthy blood donors were included in this study. Clini-
cal specimens were chosen from our serum ba~k based 
on observed IF A patterns and titers to insure a variety of 
autoantibodies as well as sera with negative IFA results. 
Sera that were positive for ANA demonstrated the classi-
cal IFA patterns of speckled, homogeneous, nucleolar 
and centromere as well as mixed and atypical patterns 
with titers ranging from I :40 to 1 :20,480. Sera positive 
for an.ticytopLasmic antibodies (ACA) demonstrated ap-
propnate IF A cytoplasmic patterns of coarse speckled, 
homogeneous, and fine speckled for antimitochondrial 
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antibody (AMA), anti-histidyl-tRNA synthetase (Jo-l), 
and anti-ribosomal RNP (rRNP), respectively with titers 
ranging from 1:40 to 1: 1,280. Because these samples 
were sent to us from other laboratories, clinical informa-
tion was not available to us. 
All specimens were stored at -20°C until assayed. 
Samples that required repeat testing were stored at 4°C, 
avoiding freeze/thaw cycles. 
Anti-Nuclear Antibodies by fFA 
All ANA IFA testing was performed using kits pur-
chased from INOV A Diagnostics (San Diego, CA). 
These kits use optimally fixed human epithelial (HEp-
2) cells as the substrate and affinity purified, fluorescein 
labeled anti-human immunoglobul1n (Ig) type G conju-
gate (from goat) for the detection of autoantibodies in 
patient sera. 
Samples were diluted 1 :40 in phosphate buffered sa-
line (PBS). Approximately 50 .uL of diluted sample and 
prediluted controls were added to wells and incubated at 
room temperature for 30 minutes in a moist chamber. 
Slides were then rinsed and submerged in PBS for 5 min-
utes. Excess PBS was shaken off and approximately 50 
J.LLoffluorescein-labeled IgG conjugate was immediately 
applied to each well and allowed to incubate at room 
temperature for 30 minutes in a moist chamber. Slides 
were washed in the same manner as above then mounted 
on coverslips using the provided mounting medium. 
Shdes were viewed at 400X (numerical aperture of 0.85 
mm) using an Olympus (Tokyo, Japan) BH-2 transmit-
ting fluorescent microscope with a 100 Watts mercury 
lamp. 
Samples showing fluorescence greater than the nega-
tive control were considered positive for ANA or ACA. 
All sera demonstrating antinuclear or anticytoplasmic 
patterns were titered to endpoint (last titer showing 1+ 
fluorescence). Antinuclear antibody testing is performed 
routinely in our laboratory and all procedures are fol-
lowed precisely as stated in the product insert. 
ANA Screening by EfA 
The EIAs included in this evaluation were provided 
by the following manufacturers/distributors: Elias USA 
(Osceola, WI), Helix Diagnostics (West Sacramento, 
CA), Sanofi Diagnostics Pasteur (Chaska, MN),. The,r-
aTest Laboratories (Chicago, IL), and Zeus SClentliic 
(Raritan, NJ). All kits employed antigens only from n~'1t­
ural sources (HEp-2 extracts, bovine spleen, and t y-
mus) with the exception of the Elias screen ~hat used a 
combination of natural and recombinant antIgens. 
These EIAs claim to detect autoantibodies responsible 
for homogeneous, peripheral, speckled, centromere, and 
nucleolar IFA patterns. Claims of detecting specific 
ANAs (SSA, SSB, Sm, RNP, SCL-70/DNA-topoisomer-
ase I, histones, dsDNA) are also stated in the inserts. All 
but the Sanofi screen claimed to detect antibody to Jo-l. 
In addition, Helix claimed to detect autoantibodies 
against rRNP, TheraTest against ssDNA, and Zeus 
against mitotic spindle apparatus. All protocols were per-
formed as stated in the package inserts. Other than ANA 
ElA kits, no other funds were derived from the manufac-
turers for these studies. 
Single Antigetl EIAs for Specific ANAs and ACAs 
Single antigen ElAs for SSA, SSB, Sm, RNP, SCL-70, 
histones, dsDNA, AMA (M2 specific), and Jo-l were 
provided by or purchased from [NOVA Diagnostics. En-
zyme immunoassays for ssDNA were purchased from 
TheraTest Laboratories. All single antigen ElAs were 
performed as stated in the package inserts. 
EIAs for SSA, SSB, Sm, RNP, SCL-70, histones, 
dsDNA, and ssDNA were incorporated into the study in 
an attempt to resolve discrepant results between IF A and 
the EIA ANA screens. Indirect fluorescent antibody-neg-
ative « 1 :40) sera giving positive EIA screen results (by 
at teast 3 EIAs) and IFA clinically significant positive 
(;;:;: I: 160) sera with negative EIA screen results (by at least 
2 EIAs) were assayed using the eight previously men-
tioned single antigen EIAs. EIAs for Jo-I and AMA M2 
were used 10 semiquantitate and confirm the presence of 
these autoantibodies that demonstrated appropriate IF A 
patterns on HEp-2. The INOY A EIAs (SSA, SSB, Sm, 
RNP, SCL-70, histones, dsDNA, Jo-l, and AMA M2) 
are semiquantitative (IU/mL lor dsDNA) for the detec-
tion of IgG autoantibodies in human sera. They. use an-
tigens affinity purified from calf thymus coated Il1 poly-
styrene microwells. All assays were pcrformed as statcd 
in the product inserts. ., . ~ 
The TheraTest anti-ssDNA is a semiquantItative EIA 
for the detection of 19G autoantibody in human se~a. 
This assay employs purified denatured DNA coated 111 
polystyrene microwells as the antigen substrate: The pro-
tocol for this assay is identical to the Theral esL ANA 
screen included in this study and was performed as stated 
in the product insert. . 
Washing steps for all EIA assays were accomplIshed by 
using a We!lwash 4 automated EIA pl~te wash~r. from 
Denley Instruments (Durham, NC). OptIcal d~nSltIeS f?r 
all ETAs were measured using a Thermomax blchromatIc 
microplate reader from Molecular Devices (Menlo Park, 
CA). 
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TABLE I. AGREEMENT, SENSITIVITY, AND SPECIFICITY OF FIVE ElA ANA SCREENS WHEN COMPARED 
WITH HEp-2 lFA ANA RESULTS 
IFA lFA 
+ + 
Elias Helix Sanofi 
+ 148 7 + 193 9 + 
65 332 21 330 
Agreement (%) 87.0 94.6 
Sensitivity (%) 69.5 90.2 
Specificity (%) 97.9 97.3 
EIA = enzyme immunoassay~ ANA = antinuclear antibody; IFA = indirect Uuorcsccnt antibody. 
Anti-Jo-l by Ouchterlony Double Diffusion 
Sera that demonstrated homogeneous cytoplasmic 
staining by IF A were assayed using the anti-Jo-I EIA 
listed previously. Ouchterlony double diffusion kits (pur-
chased from INOV A Diagnostics) were used to confirm 
the presence of J 0-1 antibody in samples with positive 
EIA results. 
This assay uses J 0-1 antigen partially purified from calf 
thymus for the detection of precipitating anti-Jo-l anti-
body in human sera using Ouchterlony double diffusion 
techniques. Reactions of identity, partial identity, or 
non identity were interpreted for each patient sample us-
ing a back-lighted, magnified viewing box (Behring Di-
agnostics). Samples with no reaction after 24 hours were 
further incubated (room temperature in moist chamber) 
and reexamined at 48 hours for any newly developed line 
of precipitation. Ouchterlony testing is performed rou-
tinely in our laboratory as specified in INOV A product 
inserts. 
RESULTS 
When compared to HEp-2 ANA by IFA, agreement, 
sensitivity and specificity for the five EIA ANA screens 
(Table 1) in clinical and blood bank sera combined were 
as follows: Elias: 87.0%, 69.5%. and 97.9%; Helix: 94.6%, 
90.2% and 97.3%; Sanofi: 95.0%, 93.7%, and 95.9%; 
TheraTest: 95.3%, 97.7%, and 93.5%; Zeus: 87.1%, 
96.2%, and 81.4%, respectively. Sera positive for Jo-l an-
tibodies (n = 8) were omitted from Sanofi's analyses. The 
sample positive for rRNP antibodies was included only 
in the analyses for Helix. 
Analysis of sera with discrepant results between IFA 
and ElA screens are shown in Table 2. Four of 7 sera 
that were IFA negative/EIA screen positive (by at least 3 
EIAs) showed 3 sera (samples 1, 3 and 4) contained low 
levels of antibody to histones and low to moderate levels 
of antibody to dsDNA, whereas one serum (sample 2) 
gave a result that was near the cutoff for SSA. The re-
IFA IFA lFA 
+ + + 
TheraTest Zeus 
192 14 + 208 22 + 205 63 
13 325 5 317 8 276 
95.0 95.3 87.1 
93.7 97.7 96.2 
95.9 93.5 81.4 
maining three sera (not shown) gave negative results for 
the specific ANAs. Results for samples that were IFA 
positive/EIA screen negative (by at least 2 EIAs; n == 20) 
indicated that 2 sera (samples 5 and 9) contained low 
levels of antibody to histones, 1 serum (sample 8) had a 
moderate level of antibody to dsDNA, and 2 sera (sam-
ples 6 and 7) possessed high levels of antibody to ssDNA 
only. The remaining IS sera (not shown) demonstrated 
no ANA specificity. Thus, only 3 of 20 sera (15%) which 
were IF A positive/EIA negative were found to contain 
sufficient antibody with an ANA specificity (2 high 
ssDNA/l moderate dsDNA) to be clinically significant. 
In the 202 sera from normal healthy blood donors, 
there was detectable autoantibody by IF A in 12.4% of 
samples, 1.5% of which possessed clinically significant ti-
ters by IFA (speckled 1:160, n = 2; speckled 1:2560, n == 
I). Most of the EIA screens demonstrated good perfor-
mance in screening out sera from normal individuals. 
Agreement, sensitivity, and specificity for the EIA screens 
were 99.4%, 100.0%, 99.4% for Elias; 99.4%, 100.0%, 
99.4% for Helix; 99.4%,100.0%,99.4% for Sanofi; 97.8%, 
100.0%,97.2% for TheraTest; and 79.4%, 100.0%, 79.1% 
for Zeus, respectively, when compared to IFA with these 
blood bank samples. The following blood bank sera with 
equivocal IFA results were excluded from these analyses: 
speckled 1 :40 (n = 18), speckled 1:80 (n = 2), nucleolar I: 
40 (n = 1) and cytoplasmic 1:40 (n = I). 
When screening sera with IFA titers of 1 :40 (n = 145), 
the percent positive for the EIAs were as follows: 15% 
(Elias), 14% (Helix), 32% (Sanofi), 29% (TheraTest), and 
50% (Zeus). In contrast, the percent positive in sera with 
IF A titers of 1 :80 (n = 87) increased significantly for 
most of the EIAs (Elias 22%, Helix 48%, Sanofi 54%, 
TheraTest 57%, and Zeus 7 1%) as was expected. The ma-
jority of these 232 samples demonstrated speckled or ho-
mogeneouS patterns by IF A. These samples have been 
omitted from the statistical analyses shown in Table 1 
because titers of 1:40 and 1 :80 are of equivocal clinical 






TABLE 2. SERA WITH DISCORDANT RESULTS BETWEEN EIA ANA SCREENS AND HEp·2 IFA ANA THAT CONTAINED 
DETECTABLE LEVELS OF AUTOANTIBODY BY SINGLE ANTlGEN EIAs 
Results from EIA ANA Screens Results from Single Antigen EIAs' 
No. IFA Result Elias Helix Sanoji TiJeraTes( Zeus SSA SSB Sill RNP SCL-70 Histone dsDNA 
<1:40 + + + + 5 5 7 8 II l.3t 209t 
2 <1:40 + + + 18 5 4 6 5 0.6 120 
3 <1:40 + + + + 7 8 5 8 8 IAt 342t 
4 <1:40 + + + + 5 6 6 7 8 l.2t 204t 
5 Spk 1:160 + + + 6 6 5 7 II l.3t 150 
6 Spk 1:640 + + + 4 4 6 4 6 0.9 198 
7 Hom 1:160 + 6 4 4 5 5 0.8 III 
8 Nuc 1:160 + 6 4 3 5 4 OA 381t 
9 Nuc 1:160, Spk 1:80 + + + 5 5 5 6 7 1.2t 185 
EIA = cnzyn'lC immUn()J5~Y; ANA = antinuclear antibody: IrA;: indirect fluorescent antibody; Spk :::0 speckled: Hom"" homogenous; 
Nuc ~ nudcobr . 
• CUI-offvalues for single antigen EIAsare as rollows: SSA. SSB. Sm. RNP. and SCL-70 ~ 20 U/mL: Histone ~ 1.0 U/mL: dsDNA ~ 200 
IU/mL: ssDNA ~ 99 U/mL. 
t Positive an I ib<X.!y levcl. 
ssDNA ;:t:.. "-< > ~ en 33 ~ 
0 1<' 0 
13 ~ ~ 
20 '" en :::s ~ 29 ~. ..... 
514t t:r:! 
409t ~ >-l 
0 ~ > 
0 ~ r-' 
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Because of the low sensitivity observed using the Elias 
screen (Table 1), we selected 13 sera for further evalua-
tion. These sera demonstrated classical IFA patterns 
with clinically significant titers (;;::: 1: 160) and were found 
to be negative only by the Elias screen. Further analyses 
showed variable levels of antibody (low-to-high for his-
tones, low-to-moderate for dsDNA) to dsDNA and/or 
histones in 7 of the 13 sera. 
The data for anti-Jo-l positive sera (n == 8) indicated a 
decrease in sensitivity for this autoantibody when using 
the Helix and Zeus screens. These EIAs failed to detect 
five (Helix) and two (Zeus) of the eight sera positive for 
J 0-1 antibody. The presence of antibody to J 0- I was de-
termined by both Ouchterlony double diffusion and EIA 
methods. The Elias and TheraTest screens demonstrated 
100% sensitivity for Jo-l antibody. Even though the Sa-
non screen did not claim to detect antibody to Jo-\, it 
also detected all J 0-1 positive sera. 
Although none of these screens claimed to detect 
AMA, the TheraTest and Zeus EIAs detected all AMA 
positive sera (n == 7). These sera demonstrated coarse cy-
toplasmic staining ofHEp-2 cells (1: 160-1: 1280) typical 
of AMA and all were highly positive for the M2 antigen 
by EIA. 
We obtained one serum sample positive for rRNP an-
tibody from INOVA diagnostics to include in our study. 
This sample demonstrated fine smooth speckling of the 
cytoplasm with staining of the nucleoli by IF A to a titer 
of I :320. All EIA screens gave positive results for this 
serum except the Elias screen, but only Helix claimed to 
detect this rare cytoplasmic autoantibody. 
Because most of these EIA screens begin with a HEp-
2 cellular extract, one can assume the presence of mito-
chondrial and rRNP antigens. 
Sera positive for autoantibodies that demonstrated a 
discrete atypical coarse speckling by IFA (n = 5; 1:320-
I :2560) referred to as the "pseudo-centromere" or 
"nuclear dot" pattern gave variable results between the 
EIA screens. None of the screens detected all five sera 
indicating decreased sensitivity of all the EIAs for thi~ 
atypical autoantibody. These sera were also omitted 
from the statistical analyses in Table 1 because the clini-
cal significance of this autoantibody has not yet been es-
tablished and no claims were made for detecting atypical 
ANAs. 
DISCUSSION 
This is the first comprehensive study in which ANA 
screening by EIA, employing the majority of newly de-
veloped EIA ANA screens that are commercially avail-
able has been compared to the standard IFA method and 
to each other. Monee and colleagues3 compared the He-
lix EIA ANA screen to IFA ANA using HEp-2 cellS in 
which similar findings were noted as in our study for the 
Helix screen, but data for anti-cytoplasmic autoarlti-
bodies, particularly Jo-I, are absent from that study. 
Most of these EIA ANA screens demonstrated good 
correlation with IFA. Claims of sensitivity and specificity 
in some product inserts were lower than what we have 
determined mainly because the manufacturers have used 
titers of I :40 or 1 :80 as the positive cut-off for IFA. Low 
titers such as these are often found in the normal popu-
lation and usually do not contain specific autoanti-
bodies.4- 6 Therefore, one would expect these EIAs to 
sometimes disagree with IF A titers of I :40 or I :80. In 
contrast, we chose to use 1: 160 as the positive cut-off for 
the IFA. Thus, some assays performed better with this 
more realistic cut-off than claimed in the inserts. Our 
data on sera with IF A titers of 1 :40 and 1 :80 showed av-
erage positive rates of 28% and 50%, respectively, using 
these EIA screens. 
Some screens missed few sera with IF A titers;;::: 1: 160. 
Results obtained from the analyses of discordant sera 
showed that the majority did not possess autoantibodies 
of known clinical significance. In fact, only one sample 
(sample 8; Table 2) contained significant levels of an au-
toantibody (dsDNA) specific for a rheumatic disease 
(SLE). Thus, the true false-negative rate for the better 
EIA screens was <0.5% in the 213 IFA-positive sera. 
However, there is evidence for sample 8 as well as others 
in Table 2 (samples 1, 3, and 4) that suggests false detec-
tion of antibody to dsDNA because homogenous pat-
terns were absent and there was little or no cross-reactiv-
ity with the ssDNA EIA using these sera. 
Our main interests were to determine the overall COf-
relation between these EIA screens with IF A and to each 
other whether a specific ANA was present or not. The 
TheraTest and Zeus screens had better agreement with 
IF A in the discordant sera (Table 2) that were shown to 
possess specinc ANAs. Moreover, TheraTest was the 
only screen to detect the high level of ssDNA antibody 
found in sample 7 (Table 2). However, antibodies t~ 
ssDNA are not readily detected by IF A since interphase 
and metaphase HEp-2 cells lack this antigen.7 Therefore 
the homogeneous pattern of 1: 160 for sample 7 rna; 
have been the cause of some nonspecific ANA since EIA 
c: . S 
lor hlstones and dsDNA gave negative results. There 
were other sera in the study (sample 8, Table 2; others 
not shown). in which data from further analyses did not 
correlate wlth the IF A patterns and will be investigated 
further. 
. Theser~ posi.tive for antibodies toJo-1 and rRNP were 
mcluded m thIS study to challenge specific claims for 
ACA(s) made by the manufacturers. Antibodies to JO-1 
A,J.c.P,·ApriI1996 
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are found in a sub-group of myositis patients with inter-
stitial pulmonary fibrosis (68%) with poor prognosis7,8 
and antibodies to rRNP are found in 12% to 15% ofSLE 
patients and have been strongly associated with the neu-
ropsychiatric manifestations in some lupus patients 
(90%),9,10 Both of these ACAs rarely occur in the clinical 
laboratory and specific testing is usually requested for 
their detection. Therefore, screens that showed low sen-
sitivity for Jo-I or rRNP may not be a concern for some 
reference laboratories who perform these specific tests 
separately from their regular ANA workload. We ex-
pected a substantial cost savings if approximately 70% of 
our IFA ANA workload could be eliminated by using an 
EIA screen followed by confirmation of positive results 
by IFA, According to our current IFA ANA workload, 
the data from this study, current list prices for ANA IFA 
HEp-2 kits, and the average list price for ANA EIA 
screens, we calculated a 32% increase in total cost (labor 
and reagents) if this format of ANA testing (using man-
ual methods for EIA) were to be implemented in our lab-
oratory. With our discount on IFA reagents (due to vol-
ume) and the savings in labor costs, we expect an actual 
cost savings of 16% by automating the EIA ANA screen. 
These figures will vary between laboratories depending 
on workload, reagent/labor costs and method of testing: 
manual versus automated. Most of the 32% increase is 
due to the high cost of EIA ANA screens. These are fig-
ures that must be reduced in this era of health care re-
form if the manufacturers of these assays expect accep-
tance of their product. 
Anyone routinely performing IF A ANA testing knows 
how time consuming and SUbjective the method can be, 
especially when sample volumes are high. Because 70% 
of our IFA ANA workload is negative for ANAs, a more 
efficient, objective method such as EIA to screen for 
AN As seemed to be a practical alternative. From this 
study, we conclude that some of these EIA ANA screens 
have proved to be specific and sensitive enough to assist 
in the screening portion of ANA testing. However, none 
of the EIAs in this study demonstrated 100% sensitivity 
when compared to IFA, and thus may fail to detect a few 
of the nonspecific ANAs that present atypical as well as 
classical IF A patterns on HEp-2 cells. 
FU11her details on test performances are available per 
request from the author. 
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